CTOs on the Move

Grand Rapids Clinical Oncology Program

www.grcop.org

 
Grand Rapids Clinical Oncology Program is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.grcop.org
  • 75 Sheldon Blvd SE Ste 101
    Grand Rapids, MI USA 49503
  • Phone: 616.391.1230

Executives

Name Title Contact Details

Similar Companies

The Community Health Network of Connecticut Foundation

The Community Health Network of Connecticut Foundation is a Wallingford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DAP Health

DAP Health is a health center in Palm Springs, CA that provides medical and mental healthcare, STI testing and treatment, dentistry, pharmacy, and lab services. They also offer social services, support groups, alternative therapies, and other wellness ...

Britthaven

Britthaven is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Britthaven is based in Kinston, NC. You can find more information on Britthaven at www.britthaven.com

Well Point

Well Point is a Half Moon Bay, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Massive Bio

Increasing Accessibility to Clinical Trials and Personalized Cancer Treatment Options. Every cancer patient is different and deserves treatment of the highest quality that is personalized, affordable, and easily accessible. Massive Bio translates the world-class oncology knowledge of the large cancer centers​ experts, facilitates a virtual tumor board collaboratively with the treating oncologist, and advises the patient and treating oncologist to operationalize these expert recommendations at the point of care thereby, eliminating additional time, travel, and cost. 85% of US cancer patients receive treatments in community practices where treating oncologists are overwhelmed with the influx of new tests and treatments while trying to manage their busy practices. We believe all cancer patients deserve equal access to the latest in cancer research and treatment.